CN1093903A - A kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals - Google Patents
A kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals Download PDFInfo
- Publication number
- CN1093903A CN1093903A CN93111213A CN93111213A CN1093903A CN 1093903 A CN1093903 A CN 1093903A CN 93111213 A CN93111213 A CN 93111213A CN 93111213 A CN93111213 A CN 93111213A CN 1093903 A CN1093903 A CN 1093903A
- Authority
- CN
- China
- Prior art keywords
- pipemidic acid
- pipemidic
- reveals
- normal saline
- medicinal liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229960001732 pipemidic acid Drugs 0.000 title claims abstract description 46
- 239000007788 liquid Substances 0.000 title claims abstract description 11
- 230000000741 diarrhetic effect Effects 0.000 title claims abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000003513 alkali Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 206010012735 Diarrhoea Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 238000007910 systemic administration Methods 0.000 abstract description 7
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 5
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 208000004429 Bacillary Dysentery Diseases 0.000 abstract description 3
- 208000004232 Enteritis Diseases 0.000 abstract description 3
- 206010017915 Gastroenteritis shigella Diseases 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 201000005113 shigellosis Diseases 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is a kind of treatment diarrheal coloclysis medicinal liquid, mainly contains the pipemidic acid sheet, can be the mixture of pipemidic acid, normal saline, alkali, also can be the mixture of pipemidic acid and glycerol.The present invention has changed route of administration, and medicine directly acts on diseased region, more can bring into play powerful sterilization, bacteriostasis than systemic administration, has avoided the antibiotic toxicity, side effect of systemic administration simultaneously.The bacillary dysentery, enteritis, ulcerative colitis etc. that to treatment with diarrhoea are primary symptom have tangible curative effect, cure rate height.
Description
The present invention is a kind of treatment diarrheal coloclysis medicinal liquid, mainly contains pipemidic acid.
The disease that with diarrhoea is primary symptom is more common in cellularity dysentery, enteritis, ulcerative colitis etc.To these treatment of diseases, all with oral, intramuscular injection or intravenous drip antibiotic, Claritin is main, but the not good enough chronic disease that develops into of curative effect sometimes is not easy radical cure and causes suffering to patient.And above-mentioned Therapeutic Method all has certain difficulty for child patient.Use antibiotic too much simultaneously, be easy to generate poison, pay reaction.As the pipemidic acid tablet is oral medication, and treatment diarrhoea is had certain curative effect, but for than the severe disease feelings, curative effect is relatively poor.
The object of the present invention is to provide a kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid to reveal, change route of administration, overcome the shortcoming of systemic administration, to treatment diarrhoea curative effect height, cure rate height.
The objective of the invention is to realize in the following way:
Treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals, and comprises the pipemidic acid powder, normal saline and alkali.
Purpose of the present invention can also realize in the following way:
It is 9-10.5 that the addition of alkali makes the PH of medicinal liquid, the one, increased the dissolubility of pipemidic acid, and the 2nd, make medicinal liquid present advantages of higher stability.Alkali can be selected NaOH or NaHCO for use
3Saturated solution adopts the PH reagent paper can measure pH value very easily.
Comprise pipemidic acid 0.5-1.5g in the 50ml normal saline, optimised quantity is 0.5-1.0g.
Pipemidic acid of the present invention preferably adds antiseptic in revealing, and to increase stability of drug, makes the storage of its energy long period, and antiseptic is the 0.01-0.02 gram in the 50ml normal saline.
A kind of better embodiment of the present invention is the pipemidic acid that adds 0.5-1.5g in the 50ml normal saline, 0.01-0.02g antiseptic, PH is 9-10.5, antiseptic can be selected nipalgin for use, the optimised quantity that pipemidic acid adds is the 0.5-1.0 gram, and the described mix homogeneously of respectively forming gets final product.
Purpose of the present invention can also realize in the following way:
The treatment diarrheal is irritated decoction liquid pipemidic acid and is revealed, and comprises pipemidic acid and glycerol, is good to contain pipemidic acid 0.5-1.5g in the 50ml glycerol.
Glycerol has the healing of the ulcer surface of promotion, and antisepsis has special efficacy to the treatment ulcerative colitis behind the adding pipemidic acid.
By the present invention, some other antibiolics also can adopt form of the present invention to treat disease.
Advantage of the present invention:
＜1 〉, the present invention is a kind of enema, directly acts on diseased region-colon after the medicine coloclysis, and the colonic drug level is increased, the efficacy of a drug is concentrated, more can bring into play bigger sterilization, bacteriostasis than systemic administration, avoid systemic administration simultaneously, antibiotic poison, pair effect.
＜2 〉, the present invention makes simply, and is easy to use, basic hospital, clinic, patient can use under family members help.It is uncooperative particularly to have solved the child patient oral medication, fears the problem of pin.
＜3 〉, the pipemidic acid that contains pipemidic acid, normal saline, alkaline matter be exposed at bring down a fever, pain relieving, antidiarrheal, the multiple normal aspects curative effect of stool all is significantly improved than systemic administration.
＜4 〉, the present invention except that having anti-infectious function, can also help to discharge intravital part toxin, the effect that alleviates the whole body poisoning symptom is arranged.
＜5 〉, by matched group relatively, the present invention has tangible raising to being that the bacillary dysentery, enteritis, ulcerative colitis etc. of primary symptom have good curative effect with diarrhoea than systemic administration.
Case one:
Open * *, man, 60 years old, retired worker.It is surplus to suffer from chronic bacillary dysentery 8 years, recurs whenever fatigue, cold drinks and snachs, climate change, all invalid with multiple antibiotic and Chinese medicine.Mainly show as: stomachache, diarrhoea, passage of loose stools band dope, weak, lack of appetite.Through being produce effects 2 times with the present invention's (containing pipemidic acid, normal saline, alkaline matter) coloclysis, transference cure after 6 times, promptly and reuse is consolidated curative effect for 20 times, drug withdrawal is not recurred later six months again.
Case two:
Zhai * *, woman, 57 years old.Year surplus because of stomachache, diarrhoea, the per rectum spectroscopy is diagnosed as ulcerative colitis, the oral administration norfloxacin, and pipemidic acid, the coloclysis metronidazole, prednisone, gentamycin etc. are all invalid.Through with produce effects after the coloclysis of the present invention 6 times, stomachache disappears, diarrhoea again.After again coloclysis consolidate curative effect 20 times, now 5 months, recurrence again.
Embodiment one:
Pipemidic acid powder 0.75g, PH=9, normal saline 50ml
Being pipemidic acid after said medicine is mixed reveals.
Embodiment two:
Pipemidic acid powder 0.5g, PH=9.8, normal saline 50ml, nipalgin 0.015g.
Embodiment three:
The 50ml normal saline, pipemidic acid 1.5g, PH=10.5, nipalgin 0.01g.
Embodiment four:
The 50ml normal saline, pipemidic acid 1.0g, PH=10, nipalgin 0.02g.
Embodiment five:
50ml glycerol, pipemidic acid powder 0.5g
Embodiment six:
50ml glycerol, pipemidic acid powder 1.5g
Claims (11)
1, a kind of treatment diarrheal coloclysis medicinal liquid pipemidic acid reveals, and it is characterized in that comprising pipemidic acid powder, normal saline and alkali.
2, pipemidic acid according to claim 1 reveals, and is characterised in that PH is 9-10.5.
3, reveal according to claim 1,2 described pipemidic acids, be characterised in that to comprise pipemidic acid powder 0.5-1.5g in the 50ml normal saline.
4, pipemidic acid according to claim 3 reveals, and the optimised quantity that is characterised in that described pipemidic acid is 0.5-1.0g.
5, reveal according to claim 1,2 described pipemidic acids, be characterised in that described alkali can adopt NaOH or saturated NaHCO
3Solution.
6, reveal according to claim 1,2 described pipemidic acids, be characterised in that also to comprise antiseptic.
7, pipemidic acid according to claim 6 reveals, and is characterised in that to comprise pipemidic acid 0.5-1.5g, antiseptic 0.01-0.02g in the 50ml normal saline.
8, pipemidic acid according to claim 6 reveals, and is characterised in that to comprise pipemidic acid 0.5-1.5g in the 50ml normal saline that nipalgin 0.01-0.02g, PH are 9-10.5.
9, pipemidic acid according to claim 8 reveals, and is characterised in that preferred compositing range is to comprise in the 50ml normal saline that pipemidic acid 0.5-1.0g, 0.01-0.02g nipalgin, PH are 9-10.5.
10, a kind of treatment diarrheal is irritated decoction liquid pipemidic acid dew, is characterised in that to comprise pipemidic acid powder and glycerol.
11, pipemidic acid according to claim 10 reveals, and is characterised in that and contains pipemidic acid 0.5-1.5g in the 50ml glycerol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93111213A CN1050994C (en) | 1993-04-24 | 1993-04-24 | Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93111213A CN1050994C (en) | 1993-04-24 | 1993-04-24 | Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1093903A true CN1093903A (en) | 1994-10-26 |
| CN1050994C CN1050994C (en) | 2000-04-05 |
Family
ID=4989016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93111213A Expired - Fee Related CN1050994C (en) | 1993-04-24 | 1993-04-24 | Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1050994C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048730C (en) * | 1998-04-23 | 2000-01-26 | 河南省新乡市第二人民医院 | Zinc pipemidate its synthetic process and zinc pipemidate ointment |
| CN105250305A (en) * | 2015-10-13 | 2016-01-20 | 康普药业股份有限公司 | Pipemidic acid pharmaceutical composition |
| CN111700907A (en) * | 2020-07-24 | 2020-09-25 | 安徽克瑞迪医疗科技有限公司 | Liquid dressing and configuration method |
-
1993
- 1993-04-24 CN CN93111213A patent/CN1050994C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048730C (en) * | 1998-04-23 | 2000-01-26 | 河南省新乡市第二人民医院 | Zinc pipemidate its synthetic process and zinc pipemidate ointment |
| CN105250305A (en) * | 2015-10-13 | 2016-01-20 | 康普药业股份有限公司 | Pipemidic acid pharmaceutical composition |
| CN111700907A (en) * | 2020-07-24 | 2020-09-25 | 安徽克瑞迪医疗科技有限公司 | Liquid dressing and configuration method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1050994C (en) | 2000-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5427799A (en) | Sustained release composition and method utilizing xanthan gum and an active ingredient | |
| US5102666A (en) | Calcium polycarbophil controlled release composition and method | |
| Breuer et al. | Rectal irrigation with short-chain fatty acids for distal ulcerative colitis: preliminary report | |
| DE69434490T2 (en) | Compilations for cancer treatment | |
| DE2908847C3 (en) | Delayed release pharmaceutical preparation | |
| US5110605A (en) | Calcium polycarbophil-alginate controlled release composition and method | |
| DE69330180T2 (en) | FORMULATIONS CONTAINING HYALURONIC ACID | |
| DE69612755T2 (en) | TRIGLYCERIDES AND ETHYLESTERS OF PHENYLALKOIC ACIDS AND PHENYLALKOIC ACIDS FOR THE TREATMENT OF VARIOUS DISEASES | |
| KR910005858A (en) | Fatty acid therapy | |
| CN104983844A (en) | Edible composition formula with mucous-membrane restoring function and preparation process of preparation thereof | |
| CN100431547C (en) | A triptolide composite preparation for treating osteoarthritis by joint intracavity injection | |
| CN1050994C (en) | Enteroclysis medicine Liq.-Acidum pipemidicum syrup for curing diarrhea | |
| JPH03246233A (en) | Drug composition for transmucosal administration | |
| DE1917283C3 (en) | Manufacture of antimicrobial preparations | |
| Euler et al. | Failure of a cytoprotective dose of arbaprostil to heal acute duodenal ulcers: results of a multiclinic trial | |
| DE60216453T2 (en) | USE OF ANTI-DIABETICS FOR THE PREPARATION OF A TREATMENT-DRIVING MEDICAMENT | |
| CN1381259A (en) | Medicine for treating diseases of rectum and anus | |
| CN1058154C (en) | Medicine for treatment of pile | |
| EP1156831A1 (en) | Hydroxyethy starch for the painless and tissue-conserving injection of medicaments | |
| DE19732323C2 (en) | Drug combination for increased drug concentration in tissues | |
| CN1068227C (en) | Interferon liposome jellies | |
| CN1663600B (en) | Compound preparation composed of ginkgo leaf extracts and medicines promoting cerebral metabolism and its application | |
| JPS63196517A (en) | Antihypoxic and application | |
| CN1399957A (en) | Application of shikonin and its derivative in pharmaceutical industry | |
| CN1117563C (en) | Analgesic composition for cancers in digestive system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |